Stock Events

Stock Events

ProMIS Neurosciences 

$10.54
22
+$0.16+1.54% Thursday 20:00

Statistics

Day High
10.75
Day Low
10.32
52W High
39.75
52W Low
6.27
Volume
5,900
Avg. Volume
-
Mkt Cap
344.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-7.25
-4.73
-2.21
0.31
Expected EPS
-1.46
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
0Revenue
5.56MNet Income

Analyst Ratings

18.00Average Price Target
The highest estimate is 18.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.53B
Biogen is a direct competitor in the Alzheimer's disease treatment market, focusing on advanced biologics and therapies similar to ProMIS Neurosciences.
Lilly(Eli) &
LLY
Mkt Cap1.01T
Eli Lilly is a competitor because of its significant investments in Alzheimer's disease research and development of related therapeutics, competing in the same space as ProMIS.
Pfizer
PFE
Mkt Cap149.38B
Pfizer has been involved in the development of treatments for neurological disorders, including Alzheimer's, making it a competitor in the neurodegenerative disease sector.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. competes in the Alzheimer's disease treatment market with its research and development efforts in neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie is involved in neuroscience and specifically Alzheimer's disease research, making it a competitor in the development of neurodegenerative disease treatments.
Novartis
NVS
Mkt Cap292.07B
Novartis AG is a competitor due to its extensive research and development in neurodegenerative diseases, including Alzheimer's disease.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.61B
ACADIA Pharmaceuticals focuses on the central nervous system disorders, including Alzheimer's, making it a competitor in the neuroscience field.
Ionis Pharmaceuticals
IONS
Mkt Cap12.11B
Ionis Pharmaceuticals, with its focus on RNA-targeted drug discovery and development, competes in the development of treatments for neurodegenerative diseases like Alzheimer's.

About

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Show more...
CEO
Mr. Eugene W. Williams
Employees
7
Country
United States
ISIN
CA74346M5054

Listings

STU
DE
23J.STU
XNAS
US
PMN
F
DE
23J.F
BOATS
BOATS
PMN.BOATS

0 Comments

Share your thoughts

FAQ

What is ProMIS Neurosciences stock price today?▼
The current price of PMN is $10.54 USD — it has increased by +1.54% in the past 24 hours. Watch ProMIS Neurosciences stock price performance more closely on the chart.
What is ProMIS Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProMIS Neurosciences stocks are traded under the ticker PMN.
Is ProMIS Neurosciences stock price growing?▼
PMN stock has risen by +1.84% compared to the previous week, the month change is a -1.03% fall, over the last year ProMIS Neurosciences has showed a -15.68% decrease.
What is ProMIS Neurosciences market cap?▼
Today ProMIS Neurosciences has the market capitalization of 344.54M
When is the next ProMIS Neurosciences earnings date?▼
ProMIS Neurosciences is going to release the next earnings report on August 17, 2026.
What were ProMIS Neurosciences earnings last quarter?▼
PMN earnings for the last quarter are -1.26 USD per share, whereas the estimation was -1.06 USD resulting in a -18.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProMIS Neurosciences revenue for the last year?▼
ProMIS Neurosciences revenue for the last year amounts to 0 USD.
What is ProMIS Neurosciences net income for the last year?▼
PMN net income for the last year is 5.56M USD.
How many employees does ProMIS Neurosciences have?▼
As of June 19, 2026, the company has 7 employees.
In which sector is ProMIS Neurosciences located?▼
ProMIS Neurosciences operates in the Health & Wellness sector.
When did ProMIS Neurosciences complete a stock split?▼
The last stock split for ProMIS Neurosciences was on November 28, 2025 with a ratio of 1:25.
Where is ProMIS Neurosciences headquartered?▼
ProMIS Neurosciences is headquartered in Toronto, United States.